8th pay panel in times of employed poverty & India’s wage challenge

Workplace woes and wages are in the spotlight yet again. Iconic business leaders are turning into social media heroes and villains depending on where they stand in the debate on quantity versus quality of work. Suddenly, where you stand and where you sit are both becoming important, as is a renewed discussion on work culture, labour productivity and a widening chasm between the financial compensation of employees in general and that of the CEO or leaders at the top. There is now a new term creeping into the common lingo: Employed poverty – where workers hold jobs but are forced to cope with and survive on inadequate wages. 

Coinciding with this, there is the news of the Union cabinet approving the 8th pay commission to revise the compensation for 50 lakh central government employees and 65 lakh pensioners.

Clearly, for the government servants the goal is to protect them against inflation. There is dearness allowance on a regular basis and a pay revision every five years, which, is not linked to productivity enhancements, as pointed out by a leading economist and former banker, who does not want to be named. Therefore, is there something to learn from the public sector on wage revisions or is the mechanism of market forces and labour availability, the way forward in the private sector? Or should productivity enhancement be the deciding metric in any pay revision?

Also Read No 8th Pay Commission? Govt exploring ‘new mechanism’ to replace pay panel system Experts pick holes in govt’s claim of sharper employment growth in last decade India’s income inequality: Why income surveys matter more than global data A middle-class meltdown

Baumol’s Cost Disease

Manish Sabharwal, co-founder and vice-chairman of TeamLease, a leading staffing and human capital firm, refers to the Baumol effect or the Baumol’s cost disease put forth by William Jack Baumol, the celebrated American economist and the professor Emeritus at Princeton University, “who did a lot of work on the cost disease and how costs keep escalating without productivity going up.” The same, he says, applies to the government. “This problem is compounded by the reality that we pay too much at the bottom (within the government) and pay too little at the top. Also, across the board increases in salary blunt meritocracy.

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth